Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 12/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PER2 | O15055 | 4/20 | 0.40 |
| ▸ | CRY1 | Q16526 | 4/20 | 0.40 |
| ▸ | CRY2 | Q49AN0 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15557431 | 0.89 | HTR3A (0.58) | HTR3APER2CRY1CRY2HTR6 | |
| SCHEMBL17170615 | 0.88 | HTR3A (0.57) | HTR3APER2CRY1CRY2HTR6 | |
| SCHEMBL19970012 | 0.86 | HTR3A (0.55) | HTR3AKCNH2PER2CRY1CRY2 | |
| SCHEMBL17176277 | 0.85 | HTR3A (0.57) | HTR3AKCNH2LMNASMN1; SMN2PER2 | |
| SCHEMBL19969990 | 0.81 | HTR3A (0.53) | HTR3AKCNH2LMNAHTR6 | |
| SCHEMBL17176289 | 0.80 | SMN1; SMN2 (0.65) | HTR3ALMNASMN1; SMN2POLBHTR6 | |
| SCHEMBL17170593 | 0.76 | HTR3A (0.56) | HTR3APER2CRY1CRY2HTR6 | |
| SCHEMBL7275971 | 0.75 | KDM4E (0.55) | KCNH2POLB | |
| SCHEMBL17163414 | 0.74 | HTR3A (1.00) | HTR3A | |
| SCHEMBL17163413 | 0.74 | HTR3A (1.00) | HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695195-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-04 | — | — | US | disclosed |
| US-20160185801-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL (JP) | 2016-06-30 | — | — | US | disclosed |
| US-9303045-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20150291624-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185801-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR5A, HTR3B | HTR3A 1/4885KCNH2 1156/4885LMNA 3559/4885 |
| US-20150291624-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR5A, HTR3B | HTR3A 1/4885KCNH2 1156/4885LMNA 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.